{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:18:11Z","timestamp":1791418691629,"version":"4.3.3"},"reference-count":181,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54AR055073"],"award-info":[{"award-number":["U54AR055073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01ES004738"],"award-info":[{"award-number":["R01ES004738"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30ES005022"],"award-info":[{"award-number":["P30ES005022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.pharmthera.2017.06.008","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T06:45:38Z","timestamp":1497941138000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":220,"special_numbering":"C","title":["Anti-TNF\u03b1 therapy in inflammatory lung diseases"],"prefix":"10.1016","volume":"180","author":[{"given":"Rama","family":"Malaviya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2017.06.008_bb0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/thoraxjnl-2012-202432","article-title":"TNF\u03b1 antagonists for acute exacerbations of COPD: A randomised double-blind controlled trial","volume":"68","author":"Aaron","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group","volume":"351","author":"Abraham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0015","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.1997.03540430043031","article-title":"p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group","volume":"277","author":"Abraham","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0020","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","article-title":"Efficacy and safety of monoclonal antibody to human tumor necrosis factor \u03b1 in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-\u03b1 MAb Sepsis Study Group","volume":"273","author":"Abraham","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: A double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1165\/ajrcmb.19.2.3080","article-title":"Expression of insulin-like growth factor binding proteins in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis","volume":"19","author":"Allen","year":"1998","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/rr162","article-title":"Growth factors in idiopathic pulmonary fibrosis: Relative roles","volume":"3","author":"Allen","year":"2002","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10753-015-0224-z","article-title":"Protective effect of infliximab, a tumor necrosis factor-\u03b1 inhibitor, on bleomycin-induced lung fibrosis in rats","volume":"39","author":"Altintas","year":"2016","journal-title":"Inflammation"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1753465814537367","article-title":"Current best practice in the management of pulmonary and systemic sarcoidosis","volume":"8","author":"Amin","year":"2014","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-2999(95)00463-U","article-title":"Induction of human airway hyperresponsiveness by tumour necrosis factor-\u03b1","volume":"284","author":"Anticevich","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0060","first-page":"419","article-title":"Leukotrienes and alpha tumor necrosis factor levels in the bronchoalveolar lavage fluid of patient at risk for the adult respiratory distress syndrome","volume":"60","author":"Antonelli","year":"1994","journal-title":"Minerva Anestesiologica"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/CRIAI:27:1:035","article-title":"Differences in airway remodeling between asthma and chronic obstructive pulmonary disease","volume":"27","author":"Aoshiba","year":"2004","journal-title":"Clinical Reviews in Allergy & Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1465-9921-12-143","article-title":"Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment","volume":"12","author":"Azuma","year":"2011","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0075","first-page":"421","article-title":"Tumor necrosis factor production by human sarcoid alveolar macrophages","volume":"125","author":"Bachwich","year":"1986","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/icb.1996.73","article-title":"Tumour necrosis factor-alpha (TNF-\u03b1): The good, the bad and potentially very effective","volume":"74","author":"Barbara","year":"1996","journal-title":"Immunology and Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0085","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.200702-253ED","article-title":"Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease","volume":"175","author":"Barnes","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0090","first-page":"L979","article-title":"Silica-induced chemokine expression in alveolar type II cells is mediated by TNF-\u03b1-induced oxidant stress","volume":"276","author":"Barrett","year":"1999","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/thorax.55.1.46","article-title":"Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls","volume":"55","author":"Bauer","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0105","first-page":"36","article-title":"Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis","volume":"115","author":"Baughman","year":"1990","journal-title":"The Journal of Laboratory and Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1752-699X.2010.00214.x","article-title":"Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis","volume":"5","author":"Baydur","year":"2011","journal-title":"The Clinical Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0115","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa050580","article-title":"Evidence of a role of tumor necrosis factor \u03b1 in refractory asthma","volume":"354","author":"Berry","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/thoraxjnl-2011-200590","article-title":"Selective inhibition of intra-alveolar p55 TNF receptor attenuates ventilator-induced lung injury","volume":"67","author":"Bertok","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0125","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/toxsci\/69.2.400","article-title":"Amelioration of ozone-induced lung injury by anti-tumor necrosis factor-\u03b1","volume":"69","author":"Bhalla","year":"2002","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tcb.2015.12.002","article-title":"TNF and ROS crosstalk in inflammation","volume":"26","author":"Blaser","year":"2016","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1165\/ajrcmb.10.5.8179909","article-title":"Interleukin-4, -5, and -6 and tumor necrosis factor-\u03b1 in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines","volume":"10","author":"Bradding","year":"1994","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1081-1206(10)60528-5","article-title":"Decrease in airway mucous gene expression caused by treatment with anti-tumor necrosis factor \u03b1 in a murine model of allergic asthma","volume":"103","author":"Busse","year":"2009","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxr032","article-title":"Infliximab alleviates inflammation and ex vivo airway hyperreactivity in asthmatic E3 rats","volume":"23","author":"Cai","year":"2011","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0150","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2147\/TCRM.S967","article-title":"Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis","volume":"4","author":"Callejas-Rubio","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0155","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10067-005-0037-9","article-title":"Treatment of therapy-resistant sarcoidosis with adalimumab","volume":"25","author":"Callejas-Rubio","year":"2006","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1432-1033.1991.tb16337.x","article-title":"The molecular action of tumor necrosis factor-\u03b1","volume":"202","author":"Camussi","year":"1991","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.aller.2013.11.002","article-title":"A human monoclonal anti-TNF alpha antibody (adalimumab) reduces airway inflammation and ameliorates lung histology in a murine model of acute asthma","volume":"43","author":"Catal","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/368780","article-title":"Improvement with infliximab of a disseminated sarcoidosis in a patient with Crohn's disease","volume":"2014","author":"Chebib","year":"2014","journal-title":"Case Reports in Pulmonology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0175","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1164\/rccm.200509-1527OC","article-title":"Signal transduction pathways of tumor necrosis factor--mediated lung injury induced by ozone in mice","volume":"175","author":"Cho","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0180","doi-asserted-by":"crossref","first-page":"L537","DOI":"10.1152\/ajplung.2001.280.3.L537","article-title":"Ozone-induced lung inflammation and hyperreactivity are mediated via tumor necrosis factor-\u03b1 receptors","volume":"280","author":"Cho","year":"2001","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0185","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaci.2005.05.034","article-title":"TNF-\u03b1 induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A2 activation","volume":"116","author":"Choi","year":"2005","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0190","doi-asserted-by":"crossref","first-page":"50s","DOI":"10.1183\/09031936.01.00229701","article-title":"Cytokines in chronic obstructive pulmonary disease","volume":"34","author":"Chung","year":"2001","journal-title":"The European Respiratory Journal. Supplement"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0195","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2174\/156801005774912806","article-title":"Inflammatory mediators in chronic obstructive pulmonary disease","volume":"4","author":"Chung","year":"2005","journal-title":"Current Drug Targets. Inflammation and Allergy"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0200","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1165\/rcmb.2007-0367OC","article-title":"Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure","volume":"40","author":"Churg","year":"2009","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0205","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cytogfr.2007.04.002","article-title":"How TNF was recognized as a key mechanism of disease","volume":"18","author":"Clark","year":"2007","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0210","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2217\/imt.14.65","article-title":"Anti-TNF therapeutics for the treatment of sarcoidosis","volume":"6","author":"Crommelin","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0215","first-page":"147","article-title":"N-acetylcysteine inhibits TNF-\u03b1, sTNFR, and TGF-\u03b21 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro","volume":"26","author":"Cu","year":"2009","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0220","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mi.2015.12","article-title":"Neutralizing TNF\u03b1 restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation","volume":"8","author":"Dejager","year":"2015","journal-title":"Mucosal Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0225","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000117386","article-title":"Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: A pilot study","volume":"76","author":"Dentener","year":"2008","journal-title":"Respiration"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0230","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1440-1843.2008.01278.x","article-title":"Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma","volume":"13","author":"Deveci","year":"2008","journal-title":"Respirology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0235","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/rccm.200601-072OC","article-title":"The effects of a monoclonal antibody directed against tumor necrosis factor-\u03b1 in asthma","volume":"174","author":"Erin","year":"2006","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1043-4666(03)00117-0","article-title":"In situ localization of TNF\u03b1\/\u03b2, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue","volume":"22","author":"Ermert","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0245","doi-asserted-by":"crossref","first-page":"L279","DOI":"10.1152\/ajplung.00348.2003","article-title":"Ozone-induced production of nitric oxide and TNF-\u03b1 and tissue injury are dependent on NF-\u03baB p50","volume":"287","author":"Fakhrzadeh","year":"2004","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0250","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.taap.2007.11.012","article-title":"Regulation of caveolin-1 expression, nitric oxide production and tissue injury by tumor necrosis factor-\u03b1 following ozone inhalation","volume":"227","author":"Fakhrzadeh","year":"2008","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0255","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2006.11.032","article-title":"Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study","volume":"196","author":"Fernandes","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0260","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.4049\/jimmunol.153.5.2278","article-title":"TNF-\u03b1 production by eosinophils in upper airways inflammation (nasal polyposis)","volume":"153","author":"Finotto","year":"1994","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0265","doi-asserted-by":"crossref","first-page":"L39","DOI":"10.1152\/ajplung.2001.280.1.L39","article-title":"Overexpression of tumor necrosis factor-\u03b1 produces an increase in lung volumes and pulmonary hypertension","volume":"280","author":"Fujita","year":"2001","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI16010","article-title":"Defective TNF-\u03b1-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice","volume":"111","author":"Garcia-Ruiz","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0161-5890(02)00207-9","article-title":"Reactive oxygen intermediates in TNF signaling","volume":"39","author":"Garg","year":"2002","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0280","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4049\/jimmunol.156.4.1540","article-title":"Reactive oxygen intermediates as regulators of TNF-\u03b1 production in rat lung inflammation induced by silica","volume":"156","author":"Gossart","year":"1996","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0285","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0091-6749(91)90149-I","article-title":"Increased secretion of tumor necrosis factor \u03b1 and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction","volume":"88","author":"Gosset","year":"1991","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0290","first-page":"761","article-title":"Phenotypic and functional analysis of pulmonary microvascular endothelial cells from patients with acute respiratory distress syndrome","volume":"74","author":"Grau","year":"1996","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0295","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMra003200","article-title":"Idiopathic pulmonary fibrosis","volume":"345","author":"Gross","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0300","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3109\/01902140902887430","article-title":"Early subcutaneous administration of etanercept (Enbrel) prevents from hyperoxia-induced lung injury","volume":"35","author":"Guthmann","year":"2009","journal-title":"Experimental Lung Research"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0305","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000444690","article-title":"Successful concomitant therapy with pirfenidone and nintedanib in idiopathic pulmonary fibrosis: A case report","volume":"91","author":"Hagmeyer","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0310","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1183\/09031936.94.07061096","article-title":"Selective enhancement of GM-CSF, TNF-\u03b1, IL-1\u03b2 and IL-8 production by monocytes and macrophages of asthmatic subjects","volume":"7","author":"Hallsworth","year":"1994","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0315","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1164\/rccm.2109004","article-title":"Tumor necrosis factor-\u03b1 and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome","volume":"166","author":"Hamacher","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0320","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389557013407214","article-title":"Modifying TNF\u03b1 for therapeutic use: A perspective on the TNF receptor system","volume":"1","author":"Hasegawa","year":"2001","journal-title":"Mini Reviews in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0325","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1165\/rcmb.2011-0353OC","article-title":"Proinflammatory cytokines induce bronchial hyperplasia and squamous metaplasia in smokers: Implications for chronic obstructive pulmonary disease therapy","volume":"47","author":"Herfs","year":"2012","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0330","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1183\/09031936.00063510","article-title":"Efficacy and safety of etanercept in moderate-to-severe asthma: A randomised, controlled trial","volume":"37","author":"Holgate","year":"2011","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0335","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-\u03b1: Structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0340","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","article-title":"Tumour necrosis factor (TNF\u03b1) as a novel therapeutic target in symptomatic corticosteroid dependent asthma","volume":"60","author":"Howarth","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0345","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/pulp.1995.1004","article-title":"The effects of tumour necrosis factor \u03b1 on mediator release from human lung","volume":"8","author":"Hughes","year":"1995","journal-title":"Pulmonary Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0350","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0355","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1440-1681.2006.04320.x","article-title":"N-acetylcysteine abrogates acute lung injury induced by endotoxin","volume":"33","author":"Kao","year":"2006","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.toxlet.2008.11.015","article-title":"A clinically relevant in vitro model for evaluating the effects of aerosolized vesicants","volume":"185","author":"Karacsonyi","year":"2009","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0365","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/ajrccm.153.2.8564092","article-title":"Differences in interleukin-8 and tumor necrosis factor-\u03b1 in induced sputum from patients with chronic obstructive pulmonary disease or asthma","volume":"153","author":"Keatings","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0370","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0091-6749(97)70032-0","article-title":"Late response to allergen is associated with increased concentrations of tumor necrosis factor-\u03b1 and IL-5 in induced sputum","volume":"99","author":"Keatings","year":"1997","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0375","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2007.05.017","article-title":"Modulating leukocyte recruitment in inflammation","volume":"120","author":"Kelly","year":"2007","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0380","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1183\/09031936.94.07122109","article-title":"Effect of Haemophilus influenzae endotoxin on the synthesis of IL-6, IL-8, TNF-\u03b1 and expression of ICAM-1 in cultured human bronchial epithelial cells","volume":"7","author":"Khair","year":"1994","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0385","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2222.2005.02407.x","article-title":"Anti-tumor necrosis factor-\u03b1 antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust","volume":"36","author":"Kim","year":"2006","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0390","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0395","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/ajrccm\/145.2_Pt_1.332","article-title":"Tumor necrosis factor causes bronchial hyperresponsiveness in rats","volume":"145","author":"Kips","year":"1992","journal-title":"The American Review of Respiratory Disease"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0400","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1040-8428(01)00203-7","article-title":"A potential role of macrophage activation in the treatment of cancer","volume":"44","author":"Klimp","year":"2002","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0405","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0378-4274(98)00316-6","article-title":"Role of inflammatory cytokines and nitric oxide in hepatic and pulmonary toxicity","volume":"102-103","author":"Laskin","year":"1998","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0410","first-page":"1","article-title":"Peroxides and macrophages in the toxicity of fine particulate matter in rats","author":"Laskin","year":"2003","journal-title":"Research Report. Health Effects Institute"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0415","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.2010.05607.x","article-title":"Macrophages, reactive nitrogen species, and lung injury","volume":"1203","author":"Laskin","year":"2010","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0420","first-page":"329","article-title":"Effect of penehyclidine hydrochloride on patients with acute lung injury and its mechanisms","volume":"13","author":"Li","year":"2010","journal-title":"Chinese Journal of Traumatology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0425","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00408-012-9449-x","article-title":"Tumor necrosis factor-\u03b1 plays an initiating role in extracorporeal circulation-induced acute lung injury","volume":"191","author":"Li","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0430","doi-asserted-by":"crossref","first-page":"13799","DOI":"10.1074\/jbc.M112.433961","article-title":"Structural basis for treating tumor necrosis factor \u03b1 (TNF\u03b1)-associated diseases with the therapeutic antibody infliximab","volume":"288","author":"Liang","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0435","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1164\/ajrccm.162.4.9910097","article-title":"Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10","volume":"162","author":"Lim","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0440","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7150\/ijms.11579","article-title":"Role and new insights of pirfenidone in fibrotic diseases","volume":"12","author":"Lopez-de la Mora","year":"2015","journal-title":"International Journal of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0445","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/09629359990711","article-title":"Evaluation of inflammatory cytokine secretion by human alveolar macrophages","volume":"8","author":"Losa Garcia","year":"1999","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0450","doi-asserted-by":"crossref","first-page":"255","DOI":"10.12659\/MSM.889800","article-title":"Bronchoalveolar pH and inflammatory biomarkers in newly diagnosed IPF and GERD patients: A case-control study","volume":"20","author":"Lozo Vukovac","year":"2014","journal-title":"Medical Science Monitor"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0455","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0197-0186(96)00075-7","article-title":"Tumor necrosis factor-\u03b1 and interleukin-1 induce activation of MAP kinase and SAP kinase in human neuroma fibroblasts","volume":"30","author":"Lu","year":"1997","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0460","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1164\/rccm.200410-1349OC","article-title":"Tumor necrosis factor-\u03b1 overexpression in lung disease: A single cause behind a complex phenotype","volume":"171","author":"Lundblad","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0465","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jgm.2631","article-title":"Locally instilled tumor necrosis factor-\u03b1 antisense oligonucleotide inhibits allergic inflammation via the induction of Tregs","volume":"14","author":"Luo","year":"2012","journal-title":"The Journal of Gene Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0470","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1358\/dot.2010.46.7.1488336","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"46","author":"Maher","year":"2010","journal-title":"Drugs of Today (Barcelona, Spain: 1998)"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0475","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00540-012-1409-3","article-title":"Interleukin-18 levels reflect the long-term prognosis of acute lung injury and acute respiratory distress syndrome","volume":"26","author":"Makabe","year":"2012","journal-title":"Journal of Anesthesia"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0480","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.taap.2010.07.018","article-title":"Inflammatory effects of inhaled sulfur mustard in rat lung","volume":"248","author":"Malaviya","year":"2010","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0485","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/toxsci\/kfv161","article-title":"Attenuation of nitrogen mustard-induced pulmonary injury and fibrosis by anti-tumor necrosis factor-\u03b1 antibody","volume":"148","author":"Malaviya","year":"2015","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0490","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/SHK.0b013e3182690ea2","article-title":"Acid-induced acute lung injury in mice is associated with P44\/42 and c-Jun N-terminal kinase activation and requires the function of tumor necrosis factor \u03b1 receptor I","volume":"38","author":"Maniatis","year":"2012","journal-title":"Shock"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0495","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pupt.2009.10.007","article-title":"TNF-\u03b1 inhibitors in asthma and COPD: We must not throw the baby out with the bath water","volume":"23","author":"Matera","year":"2010","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0500","first-page":"252","article-title":"Acute lung injury and the acute respiratory distress syndrome: Pathophysiology and treatment","volume":"107","author":"Matuschak","year":"2010","journal-title":"Missouri Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.envpol.2013.01.026","article-title":"Pro-inflammatory effects and oxidative stress in lung macrophages and epithelial cells induced by ambient particulate matter","volume":"183","author":"Michael","year":"2013","journal-title":"Environmental Pollution"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0510","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/2050-6511-15-60","article-title":"Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human","volume":"15","author":"Michel","year":"2014","journal-title":"BMC Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0515","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1752-699X.2011.00276.x","article-title":"Effect of the TNF-\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: A prospective observational study using FDG-PET","volume":"6","author":"Milman","year":"2012","journal-title":"The Clinical Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0520","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2169\/internalmedicine.55.5259","article-title":"Marked improvement with pirfenidone in a patient with idiopathic pulmonary fibrosis","volume":"55","author":"Miyamoto","year":"2016","journal-title":"Internal Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0525","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1172\/JCI118029","article-title":"Expression of a tumor necrosis factor-\u03b1 transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis","volume":"96","author":"Miyazaki","year":"1995","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0530","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/thx.2007.086314","article-title":"The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: A double blind, randomised, placebo controlled trial","volume":"63","author":"Morjaria","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0535","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1183\/09031936.94.07040779","article-title":"From granuloma to fibrosis in interstitial lung diseases: Molecular and cellular interactions","volume":"7","author":"Mornex","year":"1994","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0540","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1465-9921-7-125","article-title":"Role of TNF\u03b1 in pulmonary pathophysiology","volume":"7","author":"Mukhopadhyay","year":"2006","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0545","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.tox.2009.05.010","article-title":"Role of MAPK\/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome","volume":"261","author":"Mukhopadhyay","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0550","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00005373-199305000-00002","article-title":"Combined ibuprofen and monoclonal antibody to tumor necrosis factor-\u03b1 attenuate hemodynamic dysfunction and sepsis-induced acute lung injury","volume":"34","author":"Mullen","year":"1993","journal-title":"The Journal of Trauma"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0555","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1164\/rccm.2110052","article-title":"Association between TNFA polymorphism and the development of asthma in the Japanese population","volume":"166","author":"Noguchi","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0560","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1398-9995.2005.00778.x","article-title":"Pulmonary sarcoidosis","volume":"60","author":"Nunes","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0565","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/biof.5520080105","article-title":"Regulation of tumour cell sensitivity to TNF-induced oxidative stress and cytotoxicity: Role of glutathione","volume":"8","author":"Obrador","year":"1998","journal-title":"BioFactors"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000108","article-title":"Soluble TNF mediates the transition from pulmonary inflammation to fibrosis","volume":"1","author":"Oikonomou","year":"2006","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0575","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1164\/ajrccm.163.1.2002123","article-title":"Tumor necrosis factor receptor deficiency alters matrix metalloproteinase 13\/tissue inhibitor of metalloproteinase 1 expression in murine silicosis","volume":"163","author":"Ortiz","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0580","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1165\/ajrcmb.20.4.3193","article-title":"Upregulation of the p75 but not the p55 TNF-\u03b1 receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice","volume":"20","author":"Ortiz","year":"1999","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0585","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jat.1070","article-title":"The nitrogen mustard melphalan activates mitogen-activated phosphorylated kinases (MAPK), nuclear factor-\u03baB and inflammatory response in lung epithelial cells","volume":"25","author":"Osterlund","year":"2005","journal-title":"Journal of Applied Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0590","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1202891","article-title":"Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis","volume":"190","author":"Oswald-Richter","year":"2013","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0595","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tox.2009.01.028","article-title":"Cytokine and chemokine expression patterns in lung epithelial cells exposed to components characteristic of particulate air pollution","volume":"259","author":"Ovrevik","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0600","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/15287394.2011.586940","article-title":"Pulmonary inflammatory and fibrotic responses in Fischer 344 rats after intratracheal instillation exposure to Libby amphibole","volume":"74","author":"Padilla-Carlin","year":"2011","journal-title":"Journal of Toxicology and Environmental Health. Part A"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0605","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1440-1827.1996.tb03584.x","article-title":"Co-expression of TNF\u03b1 and IL-1\u03b2 in human acute pulmonary fibrotic diseases: An immunohistochemical analysis","volume":"46","author":"Pan","year":"1996","journal-title":"Pathology International"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0610","doi-asserted-by":"crossref","first-page":"L426","DOI":"10.1152\/ajplung.00302.2004","article-title":"Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury","volume":"288","author":"Parsons","year":"2005","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0615","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1165\/ajrcmb.13.2.7542894","article-title":"Inhibition of macrophages with gadolinium chloride abrogates ozone-induced pulmonary injury and inflammatory mediator production","volume":"13","author":"Pendino","year":"1995","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0620","first-page":"257","article-title":"Is \u201ctumor necrosis factor\u201d the major effector of pulmonary fibrosis?","volume":"1","author":"Piguet","year":"1990","journal-title":"European Cytokine Network"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0625","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/344245a0","article-title":"Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis","volume":"344","author":"Piguet","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0630","first-page":"651","article-title":"Expression and localization of tumor necrosis factor-\u03b1 and its mRNA in idiopathic pulmonary fibrosis","volume":"143","author":"Piguet","year":"1993","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0635","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1183\/09031936.94.07030515","article-title":"Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice","volume":"7","author":"Piguet","year":"1994","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0640","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/toxsci\/kfg018","article-title":"Induction of chemokines by low-dose intratracheal silica is reduced in TNFR I (p55) null mice","volume":"72","author":"Pryhuber","year":"2003","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0645","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","article-title":"Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial","volume":"178","author":"Raghu","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0650","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0006-2952(00)00392-0","article-title":"Regulation of nuclear factor-\u03baB, activator protein-1, and glutathione levels by tumor necrosis factor-\u03b1 and dexamethasone in alveolar epithelial cells","volume":"60","author":"Rahman","year":"2000","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0655","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0019-5154.53175","article-title":"Biologics: Target-specific treatment of systemic and cutaneous autoimmune diseases","volume":"54","author":"Raychaudhuri","year":"2009","journal-title":"Indian Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0660","first-page":"163","article-title":"Long-term effects of mustard gas on respiratory system of Iranian veterans after Iraq-Iran war: A review","volume":"16","author":"Razavi","year":"2013","journal-title":"Chinese Journal of Traumatology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0665","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0670","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.burns.2014.05.007","article-title":"High-frequency percussive ventilation and initial biomarker levels of lung injury in patients with minor burns after smoke inhalation injury","volume":"41","author":"Reper","year":"2015","journal-title":"Burns"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0675","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1444-0903.2004.00503.x","article-title":"Cytokine gene polymorphisms in idiopathic pulmonary fibrosis","volume":"34","author":"Riha","year":"2004","journal-title":"Internal Medicine Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0680","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0685","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/ajrccm\/143.3.590","article-title":"Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome","volume":"143","author":"Roten","year":"1991","journal-title":"The American Review of Respiratory Disease"},{"issue":"Suppl. 4","key":"10.1016\/j.pharmthera.2017.06.008_bb0690","first-page":"335","article-title":"Inflammatory markers in the exhaled breath condensate of patients with pulmonary sarcoidosis","volume":"57","author":"Rozy","year":"2006","journal-title":"Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0695","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.10.008","article-title":"Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy","volume":"43","author":"Russell","year":"2013","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0700","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1183\/09031936.96.09112298","article-title":"Ozone-induced mediator release from human bronchial epithelial cells in vitro and the influence of nedocromil sodium","volume":"9","author":"Rusznak","year":"1996","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0705","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","article-title":"Potent antioxidant role of pirfenidone in experimental cirrhosis","volume":"595","author":"Salazar-Montes","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0710","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09629350020002895","article-title":"Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1\u03b2 and TNF-\u03b1","volume":"9","author":"Sasaki","year":"2000","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116775","article-title":"Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Schupp","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0720","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/bjc.1990.78","article-title":"Tumour necrosis factor: A cytokine with multiple biological activities","volume":"61","author":"Semenzato","year":"1990","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0725","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1365-2222.1995.tb03249.x","article-title":"Tumour necrosis factor alpha: A potential mediator of asthma","volume":"25","author":"Shah","year":"1995","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0730","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/01902149609050844","article-title":"Elevated levels of IL-6, INF-\u03b3, and TNF-\u03b1 in mice in response to cotton dust are modulated by anti-TNF-\u03b1 antiserum","volume":"22","author":"Shvedova","year":"1996","journal-title":"Experimental Lung Research"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0735","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000368367","article-title":"A comparative study of bronchoscopic microsample probe versus bronchoalveolar lavage in patients with burns-related inhalational injury, acute lung injury and chronic stable lung disease","volume":"89","author":"Singh","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0740","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1479-5876-10-166","article-title":"Genetic variation in the TNF receptor-associated factor 6 gene is associated with susceptibility to sepsis-induced acute lung injury","volume":"10","author":"Song","year":"2012","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0745","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pupt.2007.03.003","article-title":"TNF-\u03b1 antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease","volume":"21","author":"Suissa","year":"2008","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0750","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1165\/rcmb.2004-0288OC","article-title":"Tumor necrosis factor-\u03b1 induces transforming growth factor-\u03b21 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway","volume":"32","author":"Sullivan","year":"2005","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0755","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.taap.2010.10.027","article-title":"Role of TNFR1 in lung injury and altered lung function induced by the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide","volume":"250","author":"Sunil","year":"2011","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0760","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.yexmp.2014.05.009","article-title":"Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation","volume":"97","author":"Sunil","year":"2014","journal-title":"Experimental and Molecular Pathology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0765","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1164\/ajrccm\/145.5.1016","article-title":"High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis","volume":"145","author":"Suter","year":"1992","journal-title":"The American Review of Respiratory Disease"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0770","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000339857","article-title":"Cytokine secretion from human monocytes potentiated by P-selectin-mediated cell adhesion","volume":"160","author":"Suzuki","year":"2013","journal-title":"International Archives of Allergy and Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0775","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0780","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/art.21468","article-title":"Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis","volume":"53","author":"Sweiss","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0785","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1874306401307010021","article-title":"Monoclonal anti-TNF-\u03b1 antibodies for severe steroid-dependent asthma: A case series","volume":"7","author":"Taille","year":"2013","journal-title":"Open Respiratory Medicine Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0790","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/rmed.2000.0941","article-title":"Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease","volume":"94","author":"Takabatake","year":"2000","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0795","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/PPA.S37233","article-title":"Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis","volume":"8","author":"Takeda","year":"2014","journal-title":"Patient Preference and Adherence"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0800","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-12-93","article-title":"The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: Extended analysis of the pirfenidone trial","volume":"12","author":"Taniguchi","year":"2011","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0805","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1440-1711.2001.00980.x","article-title":"Tumour necrosis factor-\u03b1: The role of this multifunctional cytokine in asthma","volume":"79","author":"Thomas","year":"2001","journal-title":"Immunology and Cell Biology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0810","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/thorax.57.9.774","article-title":"Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma","volume":"57","author":"Thomas","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0815","first-page":"1303","article-title":"Role of tumor necrosis factor-\u03b1 in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice","volume":"151","author":"Thrall","year":"1997","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0820","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0272-5231(05)70158-1","article-title":"Pulmonary pathology of acute respiratory distress syndrome","volume":"21","author":"Tomashefski","year":"2000","journal-title":"Clinics in Chest Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0825","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1378\/chest.124.4.1526","article-title":"Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: Comparison with dexamethasone","volume":"124","author":"Tong","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0830","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0835","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.200501-147OC","article-title":"First study of infliximab treatment in patients with chronic obstructive pulmonary disease","volume":"172","author":"van der Vaart","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0840","first-page":"145","article-title":"The role of cytokines in human lung fibrosis","volume":"51","author":"Vaillant","year":"1996","journal-title":"Monaldi Archives for Chest Disease"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0845","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/BF02730667","article-title":"Acute lung injury and acute respiratory distress syndrome","volume":"71","author":"Vasudevan","year":"2004","journal-title":"Indian Journal of Pediatrics"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0850","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1164\/rccm.2202023","article-title":"Local and systemic inflammation in patients with chronic obstructive pulmonary disease: Soluble tumor necrosis factor receptors are increased in sputum","volume":"166","author":"Vernooy","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0855","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1183\/09031936.00074807","article-title":"Possible mechanisms underlying the development of cachexia in COPD","volume":"31","author":"Wagner","year":"2008","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0860","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pupt.2010.09.004","article-title":"Sulfur mustard-induced pulmonary injury: Therapeutic approaches to mitigating toxicity","volume":"24","author":"Weinberger","year":"2011","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0865","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-\u03b1 blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0870","doi-asserted-by":"crossref","first-page":"L60","DOI":"10.1152\/ajplung.00284.2006","article-title":"Differential roles of p55 and p75 tumor necrosis factor receptors on stretch-induced pulmonary edema in mice","volume":"293","author":"Wilson","year":"2007","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0875","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0880","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1183\/09031936.00140613","article-title":"Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial","volume":"43","author":"Woodruff","year":"2014","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0885","doi-asserted-by":"crossref","first-page":"L608","DOI":"10.1152\/ajplung.2000.279.3.L608","article-title":"TNF-\u03b1 increases tracheal epithelial asbestos and fiberglass binding via a NF-\u03baB-dependent mechanism","volume":"279","author":"Xie","year":"2000","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0890","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1513\/pats.201001-009SM","article-title":"Mechanisms and modification of chlorine-induced lung injury in animals","volume":"7","author":"Yadav","year":"2010","journal-title":"Proceedings of the American Thoracic Society"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0895","first-page":"2502","article-title":"Infliximab protects against pulmonary emphysema in smoking rats","volume":"124","author":"Zhang","year":"2011","journal-title":"Chinese Medical Journal"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0900","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.4049\/jimmunol.150.9.4188","article-title":"Enhanced IL-1\u03b2 and tumor necrosis factor-\u03b1 release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure","volume":"150","author":"Zhang","year":"1993","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2017.06.008_bb0905","first-page":"223","article-title":"Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis","volume":"46","author":"Ziegenhagen","year":"1998","journal-title":"Journal of Investigative Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725817301560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:55:50Z","timestamp":1692831350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725817301560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":181,"alternative-id":["S0163725817301560"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.008","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-TNF\u03b1 therapy in inflammatory lung diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}